trial, some patients with stable ischemic heart disease randomized to optimal medical therapy (OMT) crossed over to early revascularization. The predictors and outcomes of patients who crossed over from OMT to revascularization are unknown. Methods and Results-We compared characteristics of OMT patients who did and did not undergo revascularization within 12 months and created a Cox regression model to identify predictors of early revascularization. Patients' health status was measured with the Seattle Angina Questionnaire. To quantify the potential consequences of initiating OMT without percutaneous coronary intervention, we compared the outcomes of crossover patients with a matched cohort randomized to immediate percutaneous coronary intervention. Among 1148 patients randomized to OMT, 185 (16.1%) underwent early revascularization. Patient characteristics independently associated with early revascularization were worse baseline Seattle Angina Questionnaire scores and healthcare system. Among 156 OMT patients undergoing early revascularization matched to 156 patients randomized to percutaneous coronary intervention, rates of mortality (hazard ratio=0.51 [0.13-2.1]) and nonfatal myocardial infarction (hazard ratio=1.9 [0.75-4.6]) were similar, as were 1-year Seattle Angina Questionnaire scores. OMT patients, however, experienced worse health status over the initial year of treatment and more unstable angina admissions (hazard ratio=2.8 [1.1-7.5]). Conclusion-Among COURAGE patients assigned to OMT alone, patients' angina, dissatisfaction with their current treatment, and, to a lesser extent, their health system were associated with early revascularization. Because early crossover was not associated with an increase in irreversible ischemic events or impaired 12-month health status, these findings support an initial trial of OMT in stable ischemic heart disease with close follow-up of the most symptomatic patients. 
T he ideal management of chronic stable ischemic heart disease can include either optimal medical therapy (OMT) alone or OMT supplemented with revascularization, such as percutaneous coronary intervention (PCI). 1 Although the decision to proceed directly to PCI may be influenced by patient or physician preferences, the long-term outcomes of either strategy are similar, although up to a third of patients treated with OMT alone may ultimately require revascularization, and a sixth need it within a year. 2 Whether there are adverse long-term consequences of pursuing OMT alone among those patients who ultimately receive early revascularization is unknown. If adverse outcomes exist, it would be important to be able to identify such patients and offer upfront PCI rather than delay a potentially beneficial therapy. To address this current gap in knowledge, we analyzed the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial to describe patient characteristics associated with the need for early revascularization so as to identify a cohort in whom stronger consideration for immediate PCI might be warranted. We then examined the clinical outcomes of OMT patients requiring early revascularization and compared their outcomes with similar patients initially randomized to PCI. These analyses can assist in the application of the COURAGE trial to clinical practice by identifying patient factors associated with early revascularization and by clarifying the consequences of delaying PCI in such patients while attempting treatment with OMT alone.
Methods
The methods used in COURAGE have been described previously. 3 In brief, patients with both a 70% coronary stenosis and inducible myocardial ischemia by objective stress testing, or an 80% stenosis with Canadian Cardiovascular Society class III angina symptoms, were randomized to initial PCI with OMT or to OMT alone. The study protocol was approved by the human rights committee at the coordinating center and by the local institutional review boards at each participating center. Data management and statistical analyses were performed solely by the data coordinating centers that had full access to the data, with oversight by the trial's executive committee, which vouched for the accuracy and completeness of the analyses.
Definition of an Early Crossover From OMT to PCI
Patients initially randomized to OMT alone were eligible for symptom-driven, deferred PCI (crossover) if they developed deteriorating clinical status or were hospitalized for an acute coronary syndrome. Because the goal of this analysis was to investigate patients who underwent revascularization that might have been predicted at study entry, we focused on the population who underwent early crossover (ie, within 12 months of randomization), as later revascularizations may have been performed for the progression of disease in other vessels than those deemed worst at the time of randomization. 4 
Predictor Variables
Given that the purpose of this study was to identify patients in whom a strategy of initial PCI would be most appropriate, only those patient characteristics that were available at the time of randomization, including the 52 demographic, clinical, angiographic, and stress testing results shown in Table 1 , and felt to be clinically important, were considered as potential predictors of the need for early PCI. In conformity with the current philosophy of cardiovascular care embodied in clinical guidelines, 5, 6 we estimated patients' risks for 1-year mortality and assigned each patient a predicted risk category. High-risk patients would be expected to have a >3% annual mortality rate (ejection fraction <35%, Duke treadmill score <-10, reversible perfusion defect on nuclear imaging or echo stress test with anterior ischemia or >2 defects), intermediate risk patients had an estimated 1% to 3% annual mortality (ejection fraction 35%-49%, Duke treadmill score of 4 to -10, or 1-2 areas of inducible ischemia on stress testing), and low-risk patients had a <1% mortality rate and included those patients who were not at high or intermediate risk. Using this methodology, patients were assigned the highest potential category of mortality risk. In addition, to assess the magnitude of myocardial ischemia subtended by narrowed or occluded coronary arteries, a modified Duke jeopardy score was calculated for each patient.
7,8

Clinical Outcomes
For the primary analysis-predicting revascularization within 1 year after initial randomization to OMT alone-the outcome of interest was coronary revascularization within 1 year of randomization in the OMT group. To project the clinical consequences of delaying revascularization in OMT patients who ultimately received it, we examined a range of clinical outcomes for a minimum of 30-month follow-up and a median of 4.6 years. These included death from any cause, nonfatal myocardial infarction (MI), and admission for unstable angina, all of which were adjudicated by an independent committee blinded to treatment and patients' health status (their symptoms, function, and quality of life). Health status was assessed at baseline; at 1, 3, 6, and 12 months; and annually thereafter with the Seattle Angina Questionnaire (SAQ). 9, 10 The SAQ is a valid, reliable, and responsive 19-item questionnaire quantifying 5 clinically relevant domains of coronary disease, including physical limitations because of angina, recent change in angina severity, angina frequency, satisfaction with treatment for angina, and overall quality of life. Scores range from 0 to 100 for each domain, with higher scores indicating better functioning, fewer symptoms, and better quality of life. The SAQ has been demonstrated to be prognostic of subsequent mortality and acute coronary syndrome hospitalizations, 11, 12 as well as costs.
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Statistical Analysis
The first step in the analysis was to describe the frequency and time course of crossovers during the first 12 months of follow-up. All patients in the OMT group were evaluated to determine whether and when they received coronary revascularization after randomization.
WHAT IS KNOWN
• Percutaneous coronary intervention (PCI) does not improve survival or prevent myocardial infarction in patients with stable ischemic heart disease compared with optimal medical therapy (OMT).
• In Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation, a randomized trial of OMT with or without upfront PCI, some patients crossed over from OMT to PCI.
• The patient characteristics associated with a need for PCI, and whether these patients suffered any adverse consequences from delaying revascularization, are unknown.
WHAT THE STUDY ADDS
• Among the 16% of Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation trial patients who required PCI within 1 year of randomization, the strongest predictors of crossing over were severe angina, dissatisfaction with their current treatment for their stable ischemic heart disease, and the healthcare system in which they were treated.
• There was no difference in the outcomes of death or myocardial infarction between patients who crossed over from OMT and similar patients who were randomized to upfront PCI, although there was a greater risk for unstable angina admissions during follow-up.
• The health status (symptoms, function, and quality of life as assessed by the Seattle Angina Questionnaire) was worse in OMT patients who crossed over during the first year of treatment, but it was not different at 1 year. Patient characteristics, including demographic, clinical, angiographic, and health status characteristics, were then compared between OMT patients who did and did not undergo early crossover using frequencies and χ 2 tests for categorical variables and means±SD and t tests for continuous variables. A multivariable Cox regression model was then constructed to identify baseline patient characteristics independently associated with the need to cross over to revascularization within 1 year. All clinically and statistically significant variables defined by the initial comparisons were included as candidate variables in the multivariable model. To examine the influence of time on crossover rates, over which sites may have become more comfortable with the safety of OMT alone, we included a variable of calendar year in the model. Because all sites began enrollment within a year of each other, this was considered to be a reasonable measure of site comfort with trying OMT therapy alone. Backward elimination was used to arrive at the best model for each case. We conducted several sensitivity analyses to establish the robustness of our estimates. First, we imputed baseline SAQ data for the 16% of patients missing these assessments with maximum likelihood methods and repeated our analyses. Second, because patients may die within a year and before any possible procedure, we examined predictors of the combined end point of death and revascularization. The point estimates and confidence intervals (CIs) were virtually identical to the Cox model using the original data and outcome.
To examine whether patients who underwent early crossover may have suffered adverse clinical consequences (poorer health status, death, nonfatal MI, and hospitalization for unstable angina), compared with those randomized to initial PCI, we sought to identify patients within the PCI arm who were most similar to the early crossover group. Using the inclusive, multivariable prediction model with early revascularization as the outcome, each patient in the PCI arm was assigned a likelihood of requiring early PCI, had they been assigned to the OMT group. Each patient in the OMT group who crossed over to early revascularization was matched to a PCI-randomized patient within 2% of the probability of having required revascularization had OMT alone been used. This technique is analogous to propensity methods in which all available information to equate patient characteristics, other than original treatment assignment, is used. 14, 15 For the analyses of these matched pairs, the differences between the values for the OMT group requiring early revascularization and the PCI group were used for each outcome in fully adjusted analyses. Covariates included in these models were baseline health status scores, when health status was the outcome of interest, and those variables from Table 1 that were statistically significantly different (P<0.05) between groups, including Canadian Cardiovascular Society angina classification and the use of nitrates and statins at the time of randomization. If the 1-year SAQ score was missing, a value was interpolated using the last value before 1 year and the first value after 1 year. The paired clinical outcomes were analyzed using conditional logistic regression. To compare health status throughout the first year of the study, the difference (the OMT patient's value minus the PCI patient's value) was computed for all follow-up visits, and a repeated measures analysis using an unstructured covariance matrix was performed on this difference. The difference at baseline was also included as a covariate in these analyses. A P<0.01 has been used in all prior subgroup analyses of COURAGE and was considered statistically significant. All analyses were conducted with SAS v9.2.
Results
Patient Population
Among the 1148 patients assigned to an initial strategy of OMT alone, 185 (16.1%) underwent coronary revascularization within the first year of their participation in COURAGE (Figure 1 ). Among these patients, 166 (90%) underwent a PCI ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CVA, cerebrovascular accident; HbA1c, hemoglobin A1c; LAD, left anterior descending artery; LCx, left circumflex artery; MI, myocardial infarction; OMT, optimal medical therapy; PCI, percutaneous coronary intervention; RCA, right coronary artery; SAQ, Seattle Angina Questionnaire; and VA, Veterans Affairs.
*Savage 2-sample nonparametric test.
procedure, and 19 (10%) were treated with coronary artery bypass grafting surgery. Although the rate of revascularization was fairly linear through the first 8 months, among 40 patients crossing over very early (within 2 months), 21 had a hospitalization for an adjudicated MI or unstable angina and, of the remainder, 70% had increasing angina. Table 1 shows the baseline patient characteristics that differed between those who did and did not require early revascularization. Crossover patients were more likely to be women and to have hypercholesterolemia. No other statistically significant differences in sociodemographic, clinical, disease severity, or treatment characteristics were observed. The most striking difference in the populations, however, was their baseline health status. OMT patients requiring early crossover had higher Canadian Cardiovascular Society angina class and much worse diseasespecific health status at baseline, as assessed by the SAQ angina, physical limitation, treatment satisfaction, and quality of life scales (P≤0.001 for all).
Predictors of Early Revascularization
To develop a profile of the OMT patients referred for early revascularization, we created a multivariable model that included all variables that were felt to be clinically important, including diabetes mellitus, cardiac history, angiographic data, and mortality risk, or were significantly different (P<0.10) between those OMT patients who did and did not undergo early revascularization. The most important independent predictors of early revascularization were patients' baseline health status and the healthcare system in which they were treated ( Table 2 ). For each 10-point decrease in the SAQ angina frequency scale, the hazard of undergoing coronary revascularization within 1 year increased by 11% (95% CI=3%-18%). The SAQ angina stability scale, which measures the recent change in patients' angina on a 5-level scale ranging from much more frequent to much less frequent, revealed that each gradation (25 points) of more frequent angina over the past month was associated with a 37% (95% CI=18%-61%) increased use of early revascularization. The SAQ treatment satisfaction scale, which quantifies patients' satisfaction with their current angina treatment from completely dissatisfied to completely satisfied, resulted in a 16% (95% CI=3%-30%) increased frequency of early revascularization for each gradation of that scale. Finally, compared with patients treated in the Veterans Affairs (VA) healthcare system, the hazard that patients treated in Canada would undergo early revascularization was 1.37 (95% CI=0.96-1.98), and for those treated at US non-VA centers it was 1.82 (1.19-2.78). No significant interactions between healthcare system and any of the 3 SAQ scales were observed (P≥0.50 for all), suggesting that the association between baseline health status and early revascularization was similar in all 3 health systems. (Table 3) . Table 4 describes the adjusted outcomes of OMT patients requiring early revascularization compared with similar patients randomized to immediate PCI. There was no significant difference in mortality for OMT patients who crossed over early compared with similar patients randomized to PCI (odds ratio=0.51 [95% CI=0.13-2.1]). Although there was no significant difference in the rates of nonfatal MI (odds ratio=1.86 [0.75-4.6]; P=0.18), of the 45 MI events in the crossover group, 23 (51% of the MIs) occurred before revascularization, 8 (18%) at the time of revascularization (2 of these as complications of PCI), and 14 (31%) after their revascularization procedure. Thus, 49% of the MI events in the patients requiring early revascularization occurred at the time of, or after, their procedure. There was a suggestion that the crossover patients were When comparing patients' health status over the year after randomization between the 2 groups, however, the angina control and quality of life experienced by OMT patients requiring early revascularization were significantly worse over the year after randomization. Figure 2 shows the difference between the 2 groups over time. On average, the SAQ angina frequency score was 7.5 points better (95% CI=4.2-10.7 points better) in the PCI patients, and the quality of life scores were 7.9 points better (95% CI=4.1-11.7 points) over the initial year after randomization.
Outcomes of Crossover Patients Compared With Similar Patients Randomized to Initial PCI
Discussion
We found that among COURAGE patients initially randomized to OMT alone, the need for revascularization within a year of randomization was infrequent, occurring in ≈1 of 6 patients. Conversely, 5 of 6 patients with significant anatomic coronary artery disease and inducible ischemia did not require early revascularization after treatment with intensive secondary prevention, including lifestyle intervention. Importantly, the strongest predictors of the need for early revascularization were more severe angina, worse quality of life because of angina, and greater patient dissatisfaction with the current treatment of their coronary artery disease at the time of initial evaluation. The healthcare system in which patients were treated was also associated with different rates of referral for early revascularization, with greater rates in both the US non-VA and Canadian systems compared with the VA healthcare system. Importantly, there were no significant differences in survival, nonfatal MI, or 1-year health status among patients who failed OMT alone compared with similar patients randomized to immediate PCI. These data support the principal findings of the COURAGE trial that it is reasonable to attempt OMT in all patients meeting the entry criteria for the trial because there were no clear adverse consequences at 1 year after attempting to treat with OMT alone, although there were few patients at high risk for crossing over with which to compare outcomes. We did find, however, that compared with ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCSC, Canadian Cardiovascular Society class; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LAD, left anterior descending artery; LCx, left circumflex artery; LDL, low-density lipoprotein; MI, myocardial infarction; OMT, optimal medical therapy; PCI, percutaneous coronary intervention; RCA, right coronary artery; and SAQ, Seattle Angina Questionnaire.
a matched group of patients treated with initial PCI, those who required early revascularization had a trend for more frequent admissions for unstable angina and suffered significantly worse angina and quality of life during the first year of follow-up. Identifying such patients who are likely to need revascularization at an earlier time point could potentially lead to improved overall health status for the OMT treatment strategy and prevent a transient period of suboptimal health status by offering early revascularization.
The characteristics most strongly associated with early revascularization in the COURAGE patients assigned to OMT were those relating to their health status at the time of randomization. We found that patients with worsening (lower SAQ angina stability scores) and more frequent angina (lower SAQ angina frequency scores) were more likely to require early crossover, which is congruent with the clinical reality of attempting to achieve the therapeutic goal of angina elimination and optimal quality of life for patients with chronic coronary artery disease. 6, 16 Of note, the SAQ treatment satisfaction scale was also strongly associated with a need for early revascularization. Because this scale quantifies patients' satisfaction with their current treatment, it seems logical that patients dissatisfied with medical therapy before study entry, although it may not have been optimized, would also be dissatisfied with being randomized to continued OMT alone. Because some OMT patients who ultimately required early revascularization experienced more admissions for unstable angina and worse health status over the year after randomization than those initially treated with PCI, it seems reasonable to consider earlier revascularization in patients who are more symptomatic and less satisfied with the current treatment of their coronary disease. However, given that less than half of the patients with the lowest SAQ angina frequency scores (<30, suggesting daily angina) crossed over early, it is also reasonable to attempt aggressive OMT, even in these most symptomatic patients, and follow their response closely to determine whether revascularization is ultimately needed.
Interestingly, the health system in which patients were treated was independently associated with the use of early revascularization. There have been numerous studies documenting differences in the use of angiography and revascularization between the United States and Canada and within the VA and non-VA sites. [17] [18] [19] [20] [21] [22] Collectively, there is a culture of practice that favors the use of invasive procedures in non-VA US centers, although there is marked variability in the use of revascularization procedures both regionally All analyses adjust for LDL levels, CCSC, and use of nitrates and statins. For the paired analysis of the end points, a conditional logistic regression was used. For the paired analysis of the SAQ domains, the difference (OMT requiring early revascularization value minus the PCI value) was computed for all follow-up visits, and a repeated measures analysis using an unstructured covariance matrix was performed on this difference after including the baseline difference as a covariate in addition to the other adjusting covariables. AF indicates angina frequency; CI, confidence interval; CCSC, Canadian Cardiovascular Society class; LDL, low-density lipoprotein; MI, myocardial infarction; OMT, optimal medical therapy; OR, odds ratio; PCI, percutaneous coronary intervention; PL, physical limitation; SAQ, Seattle Angina Questionnaire; and QOL, quality of life.
*Adjusted for baseline SAQ AF. †Adjusted for baseline SAQ PL. ‡Adjusted for baseline SAQ QOL. §Values are means (95% CI) for the SAQ domains or counts with the odds ratio (95% CI) for the end points.
and nationally. 23, 24 Accordingly, finding differential rates of referral to revascularization in OMT patients across the 3 health systems participating in COURAGE is not surprising. Whether the results from this study, or the recently published appropriate use criteria for revascularization, 25 may alter these variations in care will require further study.
Notably, among patients randomized in the COURAGE trial, angiographic characteristics and predicted risk for subsequent mortality were not associated with early crossover among patients initially treated with OMT alone. Angiographic characteristics are commonly used to risk-stratify patients for subsequent mortality and are important methods for identifying patients most appropriate for coronary revascularization. 26, 27 In fact, the recently published appropriate use criteria for coronary revascularization identify several scenarios in which asymptomatic patients with stable coronary disease would be considered appropriate for revascularization, based on high-risk anatomy and a potential survival advantage from treatment. 25 The design of the COURAGE trial sought to prevent OMT patients from crossing over to coronary revascularization, and this finding may explain why angiographic features were not associated with a greater use of coronary revascularization. Although these factors may be associated with preemptive revascularization outside of the setting of a clinical trial, we found no evidence that their survival or MI rates differ by undergoing early PCI.
Several potential limitations should be considered when interpreting the results of this study. First, this was a secondary analysis of a clinical trial. Notably, the COURAGE trial provided aggressive medical therapy, at no cost to patients, and made a major effort to attain the therapeutic goals for secondary prevention and excellent angina control with medical therapy. [28] [29] [30] Whether similar findings and outcomes would be observed in routine clinical practice is unknown. Second, our comparisons of outcomes between 156 matched OMT and PCI patients were underpowered for many of the clinical outcomes, as reflected by the wide CIs for both mortality and nonfatal MI. Finally, we had no method for quantifying patient or physician preferences for revascularization or OMT, although the impact of healthcare systems, as outlined above, may be a partial index of physician biases toward revascularization or cultural preferences for symptom control by patients. Although patients consenting to participate in a randomized trial of revascularization likely had some equipoise, the finding that those OMT patients dissatisfied with their therapy at the time of enrollment were more likely to undergo early revascularization suggests that patient preferences were potentially important in subsequent treatment decisions.
In conclusion, although we identified baseline characteristics associated with the use of early revascularization in patients initially randomized to OMT alone in the COURAGE trial, we found that the need for early crossover was not associated with differences in 1-year health status or long-term mortality/MI outcomes. Although patients' symptoms at the time of randomization and the healthcare system in which they were treated were the strongest independent predictors of referral for early revascularization, the only adverse clinical consequences of attempting aggressive OMT was a transient decrement in their health status and more admissions for unstable angina among patients who ultimately required early revascularization. Although more research is needed to confirm whether there are other adverse consequences, such as MI or death, from delaying revascularization while attempting OMT, our data suggest that there are no irreversible consequences from starting with a more conservative management strategy. Given the unfavorable cost-effectiveness of upfront PCI from a societal perspective, 31 these data, in aggregate, support an initial trial of OMT in symptomatic patients with stable ischemic heart disease and close follow-up of the most symptomatic patients so that early revascularization can be offered if their symptoms are not adequately controlled with OMT alone.
